Stock Analiz

Fulgent Genetics, Inc. FLGT

Medical Specialities · IPO 2016 · data as of November 13, 2026

$24.66Market cap $689M
Open the interactive analysis →

Fulgent Genetics, Inc. (FLGT) is a healthcare company listed in the US with a market value of about $689M. In the twelve months to September 30, 2026 it had revenue of $330M and net income of -$91M, a net margin of -27.5%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -5% a year, a 5-year average ROIC of 5%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 69% below the current price.

About Fulgent Genetics

Fulgent Genetics is listed in the US and classified in medical specialities, IPO year 2016. Revenue went from $1M in 2014 to $323M in 2025, growth of about 65.3% a year. It was profitable in 3 of the last 10 years in our data. It spends 17% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.1
P/B0.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-0.2%
Shareholder yield1.6%
Intrinsic value vs. price−69%

Growth and quality

Revenue growth (1 yr)13.8%
Revenue growth (5 yrs, per year)-5.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-3.5%
ROIC (5-yr avg.)5.5%
Profitable years (of last 10)3
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$330M$323M$283M$289M$619M$993M$422M$33M$21M$19M$18M
Net income-$91M-$61M-$43M-$168M$143M$507M$214M-$411000-$6M-$3M-$5M
Free cash flow-$1M-$124M-$19M$5M$235M$515M$105M$4M-$3M-$2M$617000
EPS (diluted)$-3.09$-1.97$-1.41$-5.63$4.63$16.38$8.91$-0.02$-0.31$-0.14$-0.39
Net margin-27.5%-18.8%-15.1%-58.0%23.2%51.1%50.8%-1.3%-26.3%-13.4%-29.3%
ROIC—-7.2%-5.5%-13.4%10.7%42.8%38.2%-0.4%-7.4%-4.2%1.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $25.00, 1% above the current price; targets range from $25.00 to $25.00; the consensus rating is “Hold”; expected EPS is $-1.70 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Fulgent Genetics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 69% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Fulgent Genetics pay a dividend?

Not currently.

Is Fulgent Genetics a good stock to buy?

We do not give buy or sell advice. Fulgent Genetics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.